Document is current
Any future updates will be listed below
-
Authors
Lacy, Brian E.
Gagnon-Sanschagrin, Patrick
Heimanson, Zeev
Bungay, Rebecca https://orcid.org/0000-0001-7235-3292
Bellefleur, Remi
Guérin, Annie
Bumpass, Brock
Borroto, Danellys
Joseph, George
Dashputre, Ankur A.
-
Funding
Funding for this research was provided by:
Analysis Group
- License Information
-
More Information
Article History
Received: 16 November 2023
Accepted: 26 February 2024
First Online: 15 April 2024
Declarations
:
: Brian E. Lacy has served as a consultant or served on scientific advisory boards to Bausch Health US, LLC, Salix Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Abbvie, Inc., Gemelli Biotech, and Sanofi S.A. Zeev Heimanson, Brock Bumpass, and Ankur A. Dashputre are employees of Bausch Health US, LLC. Danellys Borroto was a Rutgers Institute for Pharmaceutical Industry Fellow at Bausch Health US, LLC at the time the study was conducted. George Joseph was an employee of Bausch Health US, LLC when the study was conducted and is currently employed by BioNTech US Inc. Patrick Gagnon-Sanschagrin, Rebecca Bungay, Remi Bellefleur, and Annie Guérin are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Bausch Health US, LLC, which funded the development and conduct of this study and manuscript.
: Data are de-identified and comply with the requirements of the Health Insurance Portability and Accountability Act; therefore, institutional review board exemption or informed consent was not required.
